SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge, Karolinska Institutet (“KI”) in Stockholm, Sweden, aimed at producing novel cell-based therapeutics using natural killer (“NK”) cells derived from induced pluripotent stem cells (“iPSCs”).
NVIDIA today unveiled NVIDIA® Base Command™ Platform, a cloud-hosted development hub that lets enterprises quickly move their AI projects from prototypes to production.